Barriers and Facilitators in Timely Detection of Chronic Kidney Disease: Evidences for Decision-Makers

Mejía-Avila, Rosalía Estephanie; Arredondo, Armando; Vega, Luz Angélica de la Sierra de la; Miranda, Roberto Vázquez; Montaño, Alejandro Rojas

doi:10.1016/j.arcmed.2020.04.009

Cited by 5 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results clarify the barriers to treatment that patients face, from the moment that the first signs of their illness appear [28] and show that these barriers intensify once patients begin RRT. In these trajectories, patients and their families do not have clear information about the disease and receive inadequate primary level care.…”

Section: Discussionmentioning

confidence: 56%

“…In Mexico, as in other low-and middle-income countries, routine procedures are not sufficient to detect and diagnose CKD, nor do health services have the financial capacity to meet the needs of people with ESRD [18,19,28,29,31,34,36,41]. This has resulted in a high rate of underdiagnosed and undertreated patients [16,33].…”

Section: Discussionmentioning

confidence: 99%

“…In line with national and international recommendations, our proposals include the following: a CKD patient registry including all phases of the disease; education and outreach directed at the general population; the creation of new, relevant legislation; promoting organ donation; developing and expanding the health care infrastructure; training general practitioners and nephrologists; creating multidisciplinary CKD care groups (doctors, nurses, psychologists, social workers, and nutritionists); establishing referral and counter-referral systems; and broadening RRT availability among the poorest sectors of the population [10,16,17,28,33,44].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Health care trajectories and barriers to treatment for patients with end-stage renal disease without health insurance in Mexico: a mixed methods approach

Agudelo-Botero

González-Robledo

Reyes-Morales

et al. 2020

Int J Equity Health

View full text Add to dashboard Cite

Background: Mexico has the sixth-highest premature death rate from chronic kidney disease (CKD) in the world. From 1990 to 2017, the age-standardized CKD mortality rate jumped from 28.7 to 58.1 per 100,000 inhabitants, making it the second-leading cause of death that year. Medical care for the disease is inequitable, as those without health insurance have limited access to renal replacement therapy (RRT). The objective of this study is to describe the healthcare trajectories of patients with end-stage renal disease (ESRD) in a public hospital in Mexico City and the barriers they face in receiving peritoneal dialysis and haemodialysis. Methods: This study uses a convergent mixed methods approach and is predominantly qualitative. Patients completed 199 surveys, and 42 semi-structured interviews with patients having ESRD and their families were conducted. The quantitative data were analysed using descriptive statistics, and the qualitative data were processed using a phenomenological approach. Results: It was found that 76.9% of the patients received peritoneal dialysis or haemodialysis as their first RRT. Over 30% began their treatment at least a month after a health professional prescribed it. Almost 50% had been hospitalized for complications related to the disease in the previous year, and 36% had uncertainties about their treatment. Close to 64% of the haemodialysis patients received treatment intermittently. Barriers to accessing treatment, information, contact with health services, and treatment availability were identified. Patients and their families encountered economic and emotional difficulties at every phase of their search for medical care and treatment. Conclusion: Mexico urgently needs to implement public policies related to CKD that are primarily directed at its prevention but should also implement policies directed at slowing its progression, reducing its complications, and providing funding for uninsured patients who require RRT. These policies must be based on the perspectives of human rights and equality, and the perspectives of patients, their families and the general population should be included in the policy creation process.

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Health care trajectories and barriers to treatment for patients with end-stage renal disease without health insurance in Mexico: a mixed methods approach

Agudelo-Botero

González-Robledo

Reyes-Morales

et al. 2020

Int J Equity Health

View full text Add to dashboard Cite

show abstract

“…Early diagnosis of the disease can greatly refer to the chance of curing the disease. 22 The content change of specific peptide markers detected can make a better judgment on the development of the disease. In this way, quantitative analysis of peptide markers in body fluids has become an important tool for health assessment and disease prediction.…”

Section: Introductionmentioning

confidence: 99%

“…Any change of specific analyte concentration in body fluid may provide physiological or pathological state of the organism, which makes the composition of peptide become an important marker of disease diagnosis. Early diagnosis of the disease can greatly refer to the chance of curing the disease 22 . The content change of specific peptide markers detected can make a better judgment on the development of the disease.…”

Section: Introductionmentioning

confidence: 99%

Application of peptide biomarkers in life analysis based on liquid chromatography–mass spectrometry technology

Han

Cong

et al. 2022

BioFactors

View full text Add to dashboard Cite

Biomedicine is developing rapidly in the 21st century. Among them, the qualitative and quantitative analysis of peptide biomarkers is of considerable importance for the diagnosis and therapy of diseases and the quality evaluation of drugs and food. The identification and quantitative analysis of peptides have been going on for decades. Traditionally, immunoassays or biological assays are generally used to quantify peptides in biological matrices. However, the selectivity and sensitivity of these methods cannot meet the requirements of the application. The separation and analysis technique of liquid chromatography-mass spectrometry (LC-MS) supplies a reliable alternative. In contrast to immunoassays, LC-MS methods are capable of providing the analytical prowess necessary to satisfy the demands of peptide biomarker research in the life sciences arena. This review article provides a historical account of the in-roads made by LC-MS technology for the detection of peptide biomarkers in the past 10 years, with the focus on the qualification/quantification developments and their applications.

show abstract

Service Utilization Patterns and Direct Medical Costs of Hospitalization in Patients With Renal Failure Before and After Initiating Home Peritoneal Dialysis

Torres-Toledano,

Granados-García,

Cortés-Sanabria

et al. 2024

Value in Health Regional Issues

View full text Add to dashboard Cite

Barriers and Facilitators in Timely Detection of Chronic Kidney Disease: Evidences for Decision-Makers

Cited by 5 publications

References 27 publications

Health care trajectories and barriers to treatment for patients with end-stage renal disease without health insurance in Mexico: a mixed methods approach

Health care trajectories and barriers to treatment for patients with end-stage renal disease without health insurance in Mexico: a mixed methods approach

Application of peptide biomarkers in life analysis based on liquid chromatography–mass spectrometry technology

Service Utilization Patterns and Direct Medical Costs of Hospitalization in Patients With Renal Failure Before and After Initiating Home Peritoneal Dialysis

Contact Info

Product

Resources

About